MindMed to Participate in June Investor Conferences

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

• Jefferies Global Healthcare Conference
  • Format: Presentation
  • Date and Time: Thursday, June 5, 2025 at 12:50 PM ET
  • Location: New York, NY
  • Webcast Link: Jefferies Global Healthcare Conference
• H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
  • Format: Pre-recorded Fireside Chat
  • Date and Time: Tuesday, June 17, 2025 at 7:00 AM ET
  • Location: Virtual
  • Webcast Link: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250528715195/en/

For Media: media@mindmed.co
For Investors: ir@mindmed.co

Source: Mind Medicine Inc.

Released May 28, 2025